With this proposal, NCCP plans to continue to foster multi-institutional and multidisciplinary collaboration on the research aspects of the cancer problem. These continuing research efforts to reduce the impact and morbitity of human cancer center around Clinical, Laboratory and Epidemiological-Statistical programs that utilize shared resources and have developmental needs. The Clinical Research division plans to continue its work on NCOG, Outreach, Biological Response modifiers (BRM), and Head and Neck grants and contracts. NCOG plans greater emphasis on modality studies, including new radiation modalities, BRM, new drug developments and affiliation with national speciality study groups where appropriate. Laboratory Research's aims are threefold: to foster basic-applied-clinical science interaction, catalyze multidisciplinary/multi-institutional projects and provide organizational and administrative framework for such projects. The Experimental Cancer Therapy Group, Clonogenic Assay Group, NDDT Program Project and Radiation Forum will continue. New proposals on kinase inhibitors in cell transformation and selective bioactivation of new cytotoxic drugs are under consideration. The Epidemiological-Statistical-Cancer Control Research sections' goal involves multiple resource utilization (epidemiologists, SEER Program, Regional Cancer Incidence Network, Survey Research Unit, Public Use Research Facility, Biological Labs, Regional Cancer Councils (ISAs), NCOG, Nevada State Cancer Registry, CCRU, CCSP and Statistical Center) in pursuit of cancer problem detection, definition and resolution, the latter involving intervention methods research and implementation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA019408-09
Application #
3101632
Study Section
Cancer Center Support Grant Review Committee (CCS)
Project Start
1983-07-01
Project End
1986-06-30
Budget Start
1985-07-01
Budget End
1986-06-30
Support Year
9
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Northern California Cancer Center
Department
Type
DUNS #
City
Fremont
State
CA
Country
United States
Zip Code
94538
Hoshino, T; Ahn, D; Prados, M D et al. (1993) Prognostic significance of the proliferative potential of intracranial gliomas measured by bromodeoxyuridine labeling. Int J Cancer 53:550-5
Cohen, M B; Haber, M M; Holly, E A et al. (1991) Cytologic criteria to distinguish hepatocellular carcinoma from nonneoplastic liver. Am J Clin Pathol 95:125-30
West, D W; Slattery, M L; Robison, L M et al. (1991) Adult dietary intake and prostate cancer risk in Utah: a case-control study with special emphasis on aggressive tumors. Cancer Causes Control 2:85-94
Larson, D A; Gutin, P H; Leibel, S A et al. (1990) Stereotaxic irradiation of brain tumors. Cancer 65:792-9
Kelly, J W; Holly, E A; Shpall, S N et al. (1989) The distribution of melanocytic naevi in melanoma patients and control subjects. Australas J Dermatol 30:1-8
Harnly, M E; Swan, S H; Holly, E A et al. (1988) Temporal trends in the incidence of non-Hodgkin's lymphoma and selected malignancies in a population with a high incidence of acquired immunodeficiency syndrome (AIDS) Am J Epidemiol 128:261-7
Bottles, K; Chan, J S; Holly, E A et al. (1988) Cytologic criteria for fibroadenoma. A step-wise logistic regression analysis. Am J Clin Pathol 89:707-13
Mohle-Boetani, J C; Grosser, S; Whittemore, A S et al. (1988) Body size, reproductive factors, and breast cancer survival. Prev Med 17:634-42
Carlson, R W; Billingham, M E; Kohler, M et al. (1987) Esorubicin in refractory metastatic carcinoma of the breast: a Northern California Oncology Group Study. Cancer Treat Rep 71:427-8
Holly, E A; Kelly, J W; Shpall, S N et al. (1987) Number of melanocytic nevi as a major risk factor for malignant melanoma. J Am Acad Dermatol 17:459-68

Showing the most recent 10 out of 15 publications